Skip to main content
AI Market Watch
Loading...

Primordia Lab (元示科技)

Category: AI in Biotech / Drug Discovery

AI virtual cell (AIVC) company building a general-purpose cell foundation model, coupled with a high-throughput wet-lab feedback loop. Primordia Lab (元示科技) was founded in 2026. The company is led by Jiaqi Wu (吴佳奇). Based in Shanghai (Zhangjiang), China. Total funding raised: Approximately RMB 400M; USD equivalent not confirmed. Latest round: Pre-Series A. Key investors include Legend Capital (君联资本), Huaxia Lingtou (华夏瓴投), China Merchants China Fund (招商局中国基金), JD-affiliated fund, CDH VGC (鼎晖VGC), CMC Capital, Monolith (砺思资本), Sinovation Ventures (创新工场), Shanghai Future Industry Fund (上海未来产业基金), Daotong Investment (道彤投资), Yanyuan Ventures (燕缘创投).

Founded
2026
Headquarters
Shanghai (Zhangjiang), China
Total funding
Approximately RMB 400M; USD equivalent not confirmed

Value proposition

Predict how cells respond to different disease states, experimental conditions and interventions. A self-evolving general cell model is trained through a closed loop of model prediction, experimental validation, data feedback and model update.

Products and solutions

General cell foundation model (virtual cell), biological raw-data engine with ultra-high-throughput cell perturbation platform, dry/wet-lab closed-loop experiment and feedback platform. Primordia Lab is the AI for Science lab brand, based in Beijing Haidian and Shanghai Zhangjiang.

Unique value

Combines original algorithms (the founders contributed to Arc Institute's STATE and led STACK, a zero-shot generalizing single-cell foundation model) with in-house high-quality perturbation data production. Each experiment round is designed to yield new training and validation evidence.

Target customer

Pharmaceutical and drug-discovery R&D organizations (AI drug discovery use cases).

Industries served

Biotech, pharma and AI drug discovery, life sciences research

Technology advantage

Cross-context zero-shot generalization of the cell model without retraining (STACK lineage); ultra-high-throughput perturbation data platform; dry/wet closed-loop self-evolution (recursive self-improvement applied to biological foundation models).

How they differentiate

Pairs a founding team with direct STATE/STACK authorship and an in-house ultra-high-throughput perturbation data line, aiming at a self-evolving cell foundation model. Emphasizes evidence-driven experiment selection rather than just scaling data volume.

Main competitors

INFevo (无界进化, incubated by XtalPi), Baiyao Technology (百曜科技), Xaira Therapeutics and Noetik (overseas virtual cell players)

Major milestones

Apr 2026: Yuanshi (Shanghai) Technology Co., Ltd. founded. Jul 2026: Angel round of RMB 100M+. Oct 2026: Angel+ round of ~RMB 100M. Nov 2026: Pre-A of ~RMB 300M led by Legend Capital. Mingze Dong (STACK first author, ex-Arc Institute) joined full-time as CTO.

Growth metrics

Three funding rounds in about 4 months (Jul-Nov 2026). Registered capital RMB 1.3883M. Ex-Arc Institute CTO joined full-time. Revenue not disclosed.

Market positioning

Described at announcement as a record single-round financing in the domestic AIVC sector (nearly RMB 300M Pre-A). Positions as a foundational model and data layer for next-generation AI drug discovery in a crowded field: nearly 10 AIVC financings in China since April 2026, plus well-funded overseas peers such as Xaira and Noetik (GSK deal).

Geographic focus

China, with global ambition (founders returned from the US)

About Jiaqi Wu (吴佳奇)

Postdoctoral researcher, The Rockefeller University (Cao Lab, 2023-2026); PhD in systems biology, Peking University (Academy for Advanced Interdisciplinary Studies). Experience in bioinformatics and single-cell sequencing technology development.

Latest news about Primordia Lab (元示科技)

More AI in Biotech / Drug Discovery companies